secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001493152-25-021513
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iMDx reports Q3 2025 net loss of $10.9M, advances toward FDA submission for GraftAssureDx by year-end
--------------------------------------------------------------------------------

- Revenue $260k from lab services; gross margin 53.5%; net loss $10.9M ($0.34/sh); cash $20.2M.
- On track to submit GraftAssureDx for FDA review by year-end; expect mid-2026 commercial launch.
- 19 transplant centers engaged with GraftAssure technology; goal of 20 by year-end; 11 clinical trial sites.
- Operating expenses $11.2M include $3.4M non-cash contingent consideration change; R&D up 18% QoQ to $3.9M.
- New VP Marketing Steven Tahmooressi hired; registry study of 5,000 patients planned; expanding into heart transplant testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/0001493152-25-021513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer